产品
编 号：F181099
产品类型
规格
价格
是否有货
结构图
CAS No: 1531589-13-5
产品详情
生物活性：
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer.
体内研究：
Brolucizumab (15 mg/kg; i.p. 5 days per week for 21 or 41 days) 可减缓 mSLK-KSHV 异种移植肿瘤的生长。Brolucizumab (5-50 mg/kg; i.p. once or twice daily for 28 days) 在 U87MG 神经胶质瘤模型中延迟体内肿瘤生长。Brolucizumab (10 mg/kg; i.v.) 在小鼠中显示出快速衰退期的半衰期为 5.4-7.8 分钟，缓慢衰退期的半衰期为 1.4-1.9 小时。Animal Model:NSG mice were subcutaneously injected with mSLK-KSHV cell suspension
Dosage:15 mg/kg
Administration:I.p. 5 days per week for 21 or 41 days
Result:Significantly lowed tumor growth there was no difference in survival between experimental and combined control groups.
体外研究：
Brolucizumab (2683 nM) 抑制 VEGF-A112 诱导的 U87MG 人神经胶质瘤细胞中的 VEGFR1 磷酸化和 ZHE-483-2 GMEC 中的 VEGFR2 磷酸化。
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer.
体内研究：
Brolucizumab (15 mg/kg; i.p. 5 days per week for 21 or 41 days) 可减缓 mSLK-KSHV 异种移植肿瘤的生长。Brolucizumab (5-50 mg/kg; i.p. once or twice daily for 28 days) 在 U87MG 神经胶质瘤模型中延迟体内肿瘤生长。Brolucizumab (10 mg/kg; i.v.) 在小鼠中显示出快速衰退期的半衰期为 5.4-7.8 分钟，缓慢衰退期的半衰期为 1.4-1.9 小时。Animal Model:NSG mice were subcutaneously injected with mSLK-KSHV cell suspension
Dosage:15 mg/kg
Administration:I.p. 5 days per week for 21 or 41 days
Result:Significantly lowed tumor growth there was no difference in survival between experimental and combined control groups.
体外研究：
Brolucizumab (2683 nM) 抑制 VEGF-A112 诱导的 U87MG 人神经胶质瘤细胞中的 VEGFR1 磷酸化和 ZHE-483-2 GMEC 中的 VEGFR2 磷酸化。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备